ClinicaliQ Trial Snapshot
- Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN — Recruiting • Phase III • NCT03955445.
- What is being tested: Long-term efficacy, safety and tolerability of iptacopan, a Factor B inhibitor targeting the alternative complement pathway, in patients with C3 glomerulopathy (C3G) or idiopathic immune-complex membranoproliferative glomerulonephritis (IC-MPGN).
- Patient eligibility overview: Subjects with confirmed C3G or IC-MPGN who have completed a preceding iptacopan trial; this is an open-label extension study allowing continued access to treatment for responders and those who may benefit from ongoing therapy.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of iptacopan in subjects with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative glomerulonephritis
Eligibility Snapshot
- : - Patients must have completed the treatment period of the CLNP023X2202, CLNP023B12301 or CLNP023B12302 study on study drug
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.